At Ablantis, The goal is to reduce malaria mortality rate to 0
and attain malaria elimination by 2025.
OUR MISSION is to help national
malaria elimination by taking certain measures which are:

Malaria Testing, Treatment and Elimination

Advantages of testing?
  • Reduction in Artemisinin combination therapy ACT wastage (most fevers are not malaria)
  • No impact on mortality from non-malarial febrile illness (misdiagnosis)     
  • Avoidance of Accelerated development of Artemisinin resistance (there are no alternatives to the ACTs)
  • Credibility of health workers and health service
Who are we testing?

Ablantis will use a 3-Step approach to attack the menace that is malaria; Using a rapid malaria diagnostic test and also the latest in World Health Organisation  (WHO) approve combination therapy (ACT)  for different categories:

  • ADULTS
  • INFANTS
  • CHILDREN, AGED BETWEEN 3-7 YEARS OLD
  • JUNIORS, AGED BETWEEN 7-15
  • PREGNANT WOMEN
Why are we treating?

The essence of the treatment is to bridge the gap between those with access to ACTs and those without access, especially infants and children between the ages of 3 – 7

Who are we treating?
  • Over 13 years to Adults
  • 6 Years to 13 years
  • 1 Years to 5 years
  • Infants (6 Months to 2 years)
  • Pregnant women
Advantages of the ITTCL Project

With proper treatment these burdens will be curbed to an all time low:

  • Nigeria shoulders ~ ¼  of the world’s malaria burden, with an estimated 120 million cases per year
  • Malaria is endemic in Nigeria, with 97% (186,792,376 people) of the population at risk of infection
  • Stable/perennial transmission in all parts of the country
  • A total of approximately 300,000 malaria deaths annually
  • Malaria in pregnancy accounts for 11% of maternal mortality.
  •  Malaria is responsible for 25% of all infant-related mortality and 30% of mortality in children under five years of age.